AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00975806
Drug: Sunitinib
RxNorm normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sunitinib 37.5 mg PO daily on days 1-21 of each 21-day cycle in Cohort A or on days 1-14 in Cohorts F and G
Trial: NCT04045743
Drug: MABp1 (Bermekimab) OR Placebo
RxNorm normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Period A: patients randomized 1:1 to weekly subcutaneous treatment with 400mg Bermekimab or matched Placebo for 12 weeks
Trial: NCT04151719
Drug: Methylnaltrexone bromide (MNTX)
RxNorm normalized name: Methylnaltrexone Bromide
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylnaltrexone bromide will be administered per dose and schedule specified in the respective arm.
Trial: NCT00287846
Drug: imatinib mesylate
RxNorm normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT04045743
Drug: MABp1 (Bermekimab)
RxNorm normalized name: Bermekimab
DrugBank: Bermekimab (DB14947)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Period B: all patients treated weekly with subcutaneous 400mg Bermekimab for 12 weeks
Trial: NCT01914939
Drug: Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01406158
Drug: Solifenacin Succinate Formulation A
RxNorm normalized name: Solifenacin Succinate
DrugBank: Solifenacin (DB01591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral suspension
Trial: NCT01406158
Drug: Solifenacin Succinate Formulation B
RxNorm normalized name: Solifenacin Succinate
DrugBank: Solifenacin (DB01591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral suspension
Trial: NCT01406158
Drug: Solifenacin Succinate
RxNorm normalized name: Solifenacin Succinate
DrugBank: Solifenacin (DB01591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral tablet
Trial: NCT00331084
Drug: moxifloxacin / dexamethasone
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 gtt 4x/day, 15 days
Trial: NCT04884906
Drug: Albumin Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 260mg/m2, iv, d1, Q3W, a total of 6 cycles
Trial: NCT04884906
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 80-120mg/m2, iv, d1-3, Q3W, a total of 6 cycles
Trial: NCT03431142
Drug: Clopidogrel
RxNorm normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Additional 9 months of clopidogrel monotherapy after 9-12 months of DAPT (aspirin+clopidogrel)
Trial: NCT03431142
Drug: Clopidogrel+aspirin
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Additional 9 months of clopidogrel plus aspirin after 9-12 months of DAPT (aspirin+clopidogrel)
Trial: NCT02545452
Drug: Anastrozole / Levonorgestrel (BAY98-7196)
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Release rate of the IVR: 1050 μg/d ATZ + 40 μg/d LNG
Trial: NCT02545452
Drug: Gyno-Daktarin
RxNorm normalized name: Gyno-Daktarin
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400 mg miconazole nitrate per day for 3 consecutive days
Trial: NCT02722356
Drug: Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin administered per oxytocin group or standard practice group (see above)
Trial: NCT02545452
Drug: Sobelin vaginal creme
RxNorm normalized name: lobeline
DrugBank: Lobeline (DB05137)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg clindamycin 2-dihydrogen phosphat per day for 3 consecutive days
Trial: NCT00065390
Drug: Pyrimethamine
RxNorm normalized name: Pyrimethamine
DrugBank: Pyrimethamine (DB00205)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02545452
Drug: Patentex oval
RxNorm normalized name: ovalbumin
DrugBank: Ferrimannitol ovalbumin (DB15824)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg Nonoxynol-9 per day for 3 consecutive days
Trial: NCT00648362
Drug: Glimepiride Tablets 1 mg
RxNorm normalized name: glimepiride Oral Tablet
DrugBank: Glimepiride (DB00222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1mg, single dose fasting
Trial: NCT00457990
Drug: Oral administration of ferrous sulphate
RxNorm normalized name: ferrous fumarate Oral Capsule
DrugBank: Ferrous tartrate (DB13639)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01613495
Drug: Octreotide
RxNorm normalized name: Octreotide
DrugBank: Octreotide (DB00104)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: They will be admitted to the inpatient unit of the OCTRI for testing six times. During each of these visits, testing will include measuring how well glucose (sugar) is processed, how much energy is burned off as heat, their amount of body fat, levels of the hormone ghrelin, and how much food is eaten at a meal. After the first study visit, subjects will begin monthly treatment with either the study drug or a placebo (an inactive substance), which will be continued for the first six months of the study. For the last six months of the study, subjects will be switched to the opposite treatment. During these study periods participants will return monthly for administration of study medication, physical examination, and blood draw to check liver enzymes.
Trial: NCT03399786
Drug: evinacumab
RxNorm normalized name: Evinacumab
DrugBank: Evinacumab (DB15354)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: IV administration of evinacumab
Trial: NCT01607073
Drug: Verapamil
RxNorm normalized name: Verapamil
DrugBank: Verapamil (DB00661)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Verapamil will be prepared as a solution. A 50mg/ml oral suspension may be made with immediate release tablets and either a 1:1 mixture of Ora-Sweet and Ora-Plus or a 1:1 mixture of Ora-Sweet SF and Ora-Plus will be used.~Children will start on a 4 weeks titration period:~Week 1: 1mg/kg/day divided BID Week 2: 2mg/kg/day divided BID or TID Week 3: 3mg/kg/day divided BID or TID Week 4: 4mg/kg/day divided TID~In event of adverse events, and in consultation with the family and treating physician, the dosage may be decreased to 2mg/kg/day and remain at that dose for the remainder of the study.
Trial: NCT00433667
Drug: RWJ-333369
RxNorm normalized name: RWJ-800088
DrugBank: RWJ-800088 (DB18693)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01624116
Drug: Acarbose
RxNorm normalized name: Acarbose
DrugBank: Acarbose (DB00284)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tab.Acarbose 50mg BD for one day in addition to existing medication to 10% of patients in each treatment arm.
Trial: NCT01624116
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients on metformin monotherapy prior to Ramadan will continue on it, in the same dose
Trial: NCT01624116
Drug: Metformin/ Glimepride
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin 500mg and Glimepride 1mg in a combination tablet. Dosage frequency BD
Trial: NCT01624116
Drug: Metformin/Sitagliptin
RxNorm normalized name: METFORMIN/SITAGLIPTIN
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin 500 and sitagliptin 50mg in a combination tablet,dosage frequency BD.
Trial: NCT00624273
Drug: Sildenafil therapy
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral use
Trial: NCT00963313
Drug: Adalimumab (HUMIRA®)
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Prefilled syringes containing 40 mg Adalimumab in 0.8 ml injection solution. Study drug will be subcutaneously self-administered every 2 weeks during 24 weeks.
Trial: NCT02963766
Drug: Dulaglutide
RxNorm normalized name: DULAGLUTIDE
DrugBank: Dulaglutide (DB09045)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administered SC
Trial: NCT00006190
Drug: Nelfinavir mesylate
RxNorm normalized name: Nelfinavir Mesylate
DrugBank: Nelfinavir (DB00220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00006190
Drug: Stavudine
RxNorm normalized name: Stavudine
DrugBank: Stavudine (DB00649)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00006190
Drug: Lamivudine
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00006190
Drug: Efavirenz
RxNorm normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00237497
Drug: Ramelteon
RxNorm normalized name: Ramelteon
DrugBank: Ramelteon (DB00980)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ramelteon 8 mg, tablets, orally, once daily for up to 28 nights.
Trial: NCT00237497
Drug: Zopiclone
RxNorm normalized name: zopiclone
DrugBank: Zopiclone (DB01198)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zopiclone 7.5 mg, tablets, orally, once daily for up to 28 nights.
Trial: NCT01941329
Drug: Intravitreous injection of ranibizumab
RxNorm normalized name: ranibizumab Injection
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02410590
Drug: Rocuronium
RxNorm normalized name: Rocuronium
DrugBank: Rocuronium (DB00728)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00950846
Drug: Busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Day -9, -8, -7 and -6~Patients less than or equal to 12 kg: 1.1 mg/kg/dose IV every 6 hours for 16 doses total; patients \>12 kg: 0.8 mg/kg/dose IV every 6 hours for 16 doses.
Trial: NCT00950846
Drug: Cytoxan
RxNorm normalized name: Cytoxan
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: (50 mg/kg/dose) will be given IV on Days -5, - 4, -3, and -2 over 2 hours (can be given over 1 to 4 hours as determined by the treating physician). The total dose to be given over 4 days is 200 mg/kg.
Trial: NCT00950846
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/m2/day IV over 1 hour for patients greater than 10 kg, or 1.3 mg/kg/day for patients less than or equal to 10 kg.
Trial: NCT02410590
Drug: Sugammadex
RxNorm normalized name: Sugammadex
DrugBank: Sugammadex (DB06206)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02410590
Drug: Cisatracurium
RxNorm normalized name: Cisatracurium
DrugBank: Cisatracurium (DB00565)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02410590
Drug: Neostigmine/Atropine
RxNorm normalized name: neostigmine/atropine sulfate INJECTION SYRINGE (ML)
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02410590
Drug: Succinylcholine
RxNorm normalized name: Succinylcholine
DrugBank: Succinylcholine (DB00202)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00318799
Drug: SH D01155E
RxNorm normalized name: Glutathione-SH
DrugBank: Glutathione (DB00143)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: per cycle: Days 1-21: 0.03 mg EE + 0.15 mg LNG; Days 22-28: Placebo
Trial: NCT02906397
Drug: Galunisertib 150mg by mouth twice a day
DrugBank: Galunisertib (DB11911)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: on days 1-14 of 28 day cycles
Trial: NCT04246697
Drug: Tylenol
RxNorm normalized name: Tylenol
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Used for both arms, scheduled
Trial: NCT04246697
Drug: Oxycodone
RxNorm normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Used for both arms PRN
Trial: NCT04246697
Drug: Morphine
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Used for both arms PRN
Trial: NCT04246697
Drug: Gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Used for Arm B
Trial: NCT04246697
Drug: toradol
RxNorm normalized name: Toradol
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Used for Arm B
Trial: NCT04246697
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Used for Arm B - anesthesia block
Trial: NCT03636451
Drug: 40cc buffered 0.5% lidocaine with 2 units of vasopressin paracervical block
DrugBank: Vasopressin (DB00067)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Women undergoing D\&C in the first trimester for either surgical abortion or miscarriage management will receive 40cc buffered 0.5% lidocaine with 2 units of vasopressin paracervical block before cervical dilation.
Trial: NCT03636451
Drug: 20cc 1% lidocaine with 2 units of vasopressin paracervical block
DrugBank: Vasopressin (DB00067)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Women undergoing D\&C in the first trimester for either surgical abortion or miscarriage management will be randomly assigned to receive 20cc 1% lidocaine with 2 units of vasopressin paracervical block before cervical dilation.
Trial: NCT03366974
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam 5 mg PO, Midazolam 1 mg IV
Trial: NCT02520570
Drug: ulinastatin
RxNorm normalized name: ulinastatin
DrugBank: Ulinastatin (DB12038)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: We wouldn't intervene the doctors how to treat with the patients or how to use the drug, we just observe the react of patients after treated with ulinastatin.
Trial: NCT00001421
Drug: methimazole
RxNorm normalized name: Methimazole
DrugBank: Methimazole (DB00763)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04564313
Drug: Camrelizumab treatment
RxNorm normalized name: Hongo Killer Treatment
DrugBank: Camrelizumab (DB14776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camrelizumab (SHR-1210), 200mg, I.V., Q3W
Trial: NCT00759837
Drug: Bosutinib
RxNorm normalized name: Bosutinib
DrugBank: Bosutinib (DB06616)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01466127
Drug: Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liquid metered-dose nasal spray, 30 IUs, administered once.
Trial: NCT00261027
Drug: Exemestane
RxNorm normalized name: Exemestane
DrugBank: Exemestane (DB00990)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02678104
Drug: Chlorhexidine mouth wash
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorhexidine mouth wash
Trial: NCT02157584
Drug: Telotristat etiprate
RxNorm normalized name: Telotristat etiprate
DrugBank: Telotristat (DB14218)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 × 250 mg (as free base) telotristat etiprate tablets (fed conditions /high-fat / high caloric meal)
Trial: NCT02157584
Drug: Telotristat etiprate
RxNorm normalized name: Telotristat etiprate
DrugBank: Telotristat (DB14218)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 × 250 mg (as free base) telotristat etiprate tablets (fasted conditions)
Trial: NCT00767299
Drug: arzoxifene
RxNorm normalized name: Arzoxifene
DrugBank: Arzoxifene (DB06249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg, QD, PO,24 weeks
Trial: NCT01817426
Drug: Infliximab
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT03534713
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: carboplatin aera Under curve 5 on day 1, every 21 days during 3 cycles
Trial: NCT03534713
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: paclitaxel 175 mg/m² on day 1, every 21 days during 3 cycles
Trial: NCT03534713
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 40mg/m² given once a week during 5 weeks
Trial: NCT00499460
Drug: oxycodone
RxNorm normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single administration of three 5-mg oxycodone tablets or a 15-mg dose
Trial: NCT03190967
Drug: T-DM1
RxNorm normalized name: T-DM1
DrugBank: Trastuzumab emtansine (DB05773)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: T-DM1 3.6 mg/kg intravenous (IV) every 21 days
Trial: NCT03190967
Drug: TMZ
RxNorm normalized name: TMZ
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Phase I: TMZ 30, 40 or 50 mg/m\^2 daily Phase II: TMZ at recommended phase 2 dose (RP2D) estimated in Phase I dose escalation part of the study.
Trial: NCT02678104
Drug: Intra-alveolar application of Manuka Honey
RxNorm normalized name: manuka oil
DrugBank: Honey (DB14242)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-alveolar application of Manuka Honey directly after extraction.
Trial: NCT03021590
Drug: Levofloxacin 500Mg Oral Tablet
RxNorm normalized name: Levofloxacin 500mg Oral tablet
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin 1000 mg Tablets , Esomeprazole 20 mg Capsule,Levofloxacin 500 mg Tablets and Tinidazole 500 mg Tablets all every 12 hours for 14 days all by mouth
Trial: NCT02438761
Drug: PF-05212384
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-05212384 will be delivered by intra-venous route at a fixed dose of 150 mg per week. Each treatment cycle includes four weekly injections~The treatment is administered in cycles of 28 days for a period of 4 cycles. Patients will be treated on a weekly basis continuously during 112 days or until progression.
Trial: NCT04107805
Drug: BI 1323495
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT04107805
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral administration
Trial: NCT00025454
Drug: tipifarnib
RxNorm normalized name: Tipifarnib
DrugBank: Tipifarnib (DB04960)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01852604
Drug: Samatasvir
RxNorm normalized name: Samatasvir
DrugBank: Samatasvir (DB12660)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Samatasvir (IDX719) will be supplied as 25 mg and 50 mg oral tablets.
Trial: NCT01852604
Drug: Simeprevir
RxNorm normalized name: Simeprevir
DrugBank: Simeprevir (DB06290)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Simeprevir will be supplied as 75 and 150 mg oral capsules.
Trial: NCT01852604
Drug: Ribavirin (RBV)
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ribavirin will be supplied as 200 mg oral tablets. Participants in the RBV-free arms experiencing non-response or virologic breakthrough during the treatment period will be offered RBV dosed according to the product label as an add-on to the participant's randomized treatment assignment.
Trial: NCT01852604
Drug: Ritonavir (RTV)
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ritonavir will be supplied as 80 mg/mL oral solution.
Trial: NCT02802930
Drug: Sodium chloride [NaCl]
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Negative control (200 µL, 0.9% sodium chloride \[NaCl\]) after a single 24 h application of test materials followed by irradiation with ultraviolet A (UVA) and ultraviolet B (UVB).
Trial: NCT01378845
Drug: Tracleer
RxNorm normalized name: Tracleer
DrugBank: Bosentan (DB00559)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 14 days 62,5 mg Bosentan p.o 140 days 125 mg Bosentan p.o
Trial: NCT01378845
Drug: Prostavasin
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prostavasin 60 µg i.v, 5 days per week for 2 weeks
Trial: NCT00090766
Drug: valganciclovir [Valcyte]
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: po daily (dose based on body surface area and CrCL)
Trial: NCT02941926
Drug: Ribociclib
RxNorm normalized name: Ribociclib
DrugBank: Ribociclib (DB11730)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ribociclib was centrally supplied to the investigators and administered orally once a day on days 1-21 of each 28 day cycle at a starting dose of 600 mg daily
Trial: NCT02941926
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Letrozole was procured locally and administered orally once a day on a continuous daily schedule at a dose of 2.5 mg
Trial: NCT02941926
Drug: Goserelin
RxNorm normalized name: Goserelin
DrugBank: Goserelin (DB00014)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Goserelin was procured locally and administered in men and premenopausal women as an injectable subcutaneous implant administered on day 1 starting at Cycle 1 and then every 28 days at a dose of 3.6 mg (cycle = 28 days)
Trial: NCT02941926
Drug: Leuprolide
RxNorm normalized name: Leuprolide
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprolide was procured locally and administered in men and premenopausal women as an injectable intramuscular depot administered on day 1 starting at Cycle 1 and then every 28 days at a dose of 7.5 mg (cycle= 28 days)
Trial: NCT02910765
Drug: methylene blue
RxNorm normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02910765
Drug: ozone
RxNorm normalized name: OZONE
DrugBank: Ozone (DB12510)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03661125
Drug: Saracatinib
RxNorm normalized name: Saracatinib
DrugBank: Saracatinib (DB11805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD0530 (Saracatinib) 50 mg Tablet Pink Round 7.0 mm ADM P/5406/49. Two tablets to be taken every morning for 14 days.
Trial: NCT00972777
Drug: Besifloxacin
RxNorm normalized name: Besifloxacin
DrugBank: Besifloxacin (DB06771)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Besifloxacin 0.6% administered into the study eye two times a day for three days.